Modern Chinese Medicine Group Co (HKSE:01643) ROCE % : 12.38% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Modern Chinese Medicine Group Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Modern Chinese Medicine Group Co's annualized ROCE % for the quarter that ended in Dec. 2023 was 12.38%.

Modern Chinese Medicine Group Co ROCE % Historical Data

The historical data trend for Modern Chinese Medicine Group Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modern Chinese Medicine Group Co ROCE % Chart

Modern Chinese Medicine Group Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

66.84

90.88

48.83

31.16

14.90

Modern Chinese Medicine Group Co Semi-Annual Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial						34.12	36.93	27.49	17.52	12.38

Modern Chinese Medicine Group Co ROCE % Calculation

Modern Chinese Medicine Group Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	74.717	/	( ( (560.07 - 81.915)	+	(578.097 - 53.473) )	/ 2 )
	=	74.717	/	( (478.155	+	524.624)	/ 2 )
	=	74.717	/	501.3895
	=	14.90 %

Modern Chinese Medicine Group Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	63.55	/	( ( (546.343 - 44.109)	+	(578.097 - 53.473) )	/ 2 )
	=	63.55	/	( ( 502.234	+	524.624 )	/ 2 )
	=	63.55	/	513.429
	=	12.38 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Modern Chinese Medicine Group Co (HKSE:01643) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Modern Chinese Medicine Group Co ROCE % Related Terms

Thank you for viewing the detailed overview of Modern Chinese Medicine Group Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Modern Chinese Medicine Group Co (HKSE:01643) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Modern Chinese Medicine Group Co Ltd (HKSE:01643) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 88 Jinwei Road, Hebei, Chengde, CHN, 068150

Website

http://www.cdysjdyy.com

Modern Chinese Medicine Group Co Ltd is engaged in the production of proprietary Chinese medicine. It offers both OTC and prescribed medicines intended for use by the Middle-aged and the Elderly in the PRC. Its products include Vigour and Vitality Supplement Pill, Circulation Enhancement Pill, Cardiotonic Enhancement Capsule, Kidney Invigoration Pill, Heart Wellness Capsule, Menstrual Discomfort Relief Pill, Liver Detox Tablet, and Additional Ingredient Huoxiang ZhengQi Pill and Fever-removing and Detoxification Pill. The Group has one operating segment of its business as a whole as the production of PCM. Geographically, the majority is from PRC.

Executives

Sun Xinlei	2201 Interest of corporation controlled by you
Xian Dai Sheng Wu Ke Ji Ji Tuan Kong Gu You Xian Gong Si	2101 Beneficial owner
Xie Wei	2201 Interest of corporation controlled by you

Modern Chinese Medicine Group Co (HKSE:01643) Headlines

No Headlines